WO2024201245 - COMPOSITIONS COMPRISING 5-METHOXY-2-AMINOINDAN FOR TREATMENT OF DEPRESSION

National phase entry:
Publication Number WO/2024/201245
Publication Date 03.10.2024
International Application No. PCT/IB2024/052773
International Filing Date 22.03.2024
Title **
[English] COMPOSITIONS COMPRISING 5-METHOXY-2-AMINOINDAN FOR TREATMENT OF DEPRESSION
[French] COMPOSITIONS COMPRENANT DU 5-MÉTHOXY-2-AMINOINDANE POUR LE TRAITEMENT DE LA DÉPRESSION
Applicants **
CLEARMIND LABS CORP. 101 - 1220 W 6 Ave Vancouver, BC V6H1A5, CA
Inventors
ZULOFF-SHANI, Adi c/o CLEARMIND MEDICINE INC. 20 Raoul Wallenberg Street 6971916 Tel-Aviv, IL
Priority Data
63/492,837   29.03.2023   US
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
*
International Searching Authority
*
Applicant's Legal Status
*
*
*
*
*
Entry into National Phase under
*
Translation

Recalculate

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing3164
EPO Filing, Examination47615
Japan Filing531
South Korea Filing575
USA Filing, Examination18035
MasterCard Visa

Total: 69920

The term for entry into the National Phase has expired. This quotation is for informational purposes only

Abstract[English] The present disclosure relates to pharmaceutical compositions comprising 5- methoxy-2-aminoindan, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier and/or excipient, and their use in methods of 5 treating depression by administrating said compositions to a subject in need thereof in a therapeutically effective amount.[French] La présente invention concerne des compositions pharmaceutiques comprenant du 5-méthoxy-2-aminoindane, ou un sel pharmaceutiquement acceptable de celui-ci, et au moins un support et/ou excipient pharmaceutiquement acceptable, et leur utilisation dans des méthodes de traitement de la dépression par administration desdites compositions à un sujet en ayant besoin en une quantité thérapeutiquement efficace.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙